Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Heart Transplant Test Gets Positive Coverage Decision From Tricare

NEW YORK (GenomeWeb) – Molecular diagnostics firm CareDx announced today that its AlloMap gene expression-based test for heart transplant rejection will now be covered by Tricare National Insurance.

Tricare is the healthcare program for active and returned military service members and their families. With the positive coverage decision, AlloMap will be available to the more than 9 million individuals covered by Tricare. CareDx noted that coverage will be retroactive from February 2015 onward.

"Our military service population who are covered by Tricare will now have the same access that is available through non-military health plans," CareDx CMO Jim Yee said in a statement.